EP1223811B1 - Morinda citrifolia oil - Google Patents
Morinda citrifolia oil Download PDFInfo
- Publication number
- EP1223811B1 EP1223811B1 EP00961370A EP00961370A EP1223811B1 EP 1223811 B1 EP1223811 B1 EP 1223811B1 EP 00961370 A EP00961370 A EP 00961370A EP 00961370 A EP00961370 A EP 00961370A EP 1223811 B1 EP1223811 B1 EP 1223811B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oil
- morinda citrifolia
- seeds
- fatty acid
- essential oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C5/00—Candles
- C11C5/002—Ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0003—Compounds of unspecified constitution defined by the chemical reaction for their preparation
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
Abstract
Description
- The present invention relates a process of extracting and purifying an essential oil product obtained from the Morinda citrifolia plant and to the oil itself.
- The Indian Mulberry plant, known scientifically as Morinda citrifolia L., is a shrub, or small or medium sized tree 3 to 10 meters high. It grows in tropical coastal regions around the world. The plant grows randomly in the wild, and it has been cultivated in plantations and small individual growing plots. The Indian mulberry plant has somewhat rounded branches and evergreen, opposite (or spuriously alternate), dark, glossy, wavy, prominently-veined leaves. The leaves are broadly elliptic to oblong, pointed at both ends, 10-30 cm in length and 5-15 cm wide.
- The Indian mulberry flowers are small, white, 3 to 5 lobed, tubular, fragrant, and about 1.25 cm long. The flowers develop into compound fruits composed of many small drupes fused into an ovoid, ellipsoid or roundish, lumpy body, 5-10 cm long, 5-7 cm thick, with waxy, white or greenish-white or yellowish, semi-translucent skin. The fruit contains "eyes" on its surface, similar to a potato. The fruit is juicy, bitter, dull-yellow or yellowish-white, and contains numerous red-brown, hard, oblong-triangular, winged, 2-celled stones, each containing 4 seeds.
- When fully ripe, the fruit has a pronounced odor like rancid cheese. Although the fruit has been eaten by several nationalities as food, the most common use of the Indian mulberry plant was as a red and yellow dye source. Recently, there has been an interest in the nutritional and health benefits of the Indian mulberry plant.
- It would be a significant advancement in the art to provide the essential oil from the Indian mulberry plant and to provide a process for obtaining the essential oil from the Indian mulberry plant.
- Various uses have been disclosed for substances derived from Morinda citrifolia. For example
FR 2 673 639 JP 8-217686 - The present invention is directed to a process for extracting oil from Morinda citrifolia seeds comprising the steps of drying the seeds to a moisture content less than 10%; cracking, flaking, or grinding the seeds to form ground seeds; and pressing the processed seeds to expel Morinda citrifolia oil.
- The invention is also directed to an essential oil extracted from Indian mulberry (Morinda citrifolia) seeds by the process set forth above.
- The Indian mulberry oil typically includes a mixture of several different fatty acids as triglycerides, such as palmitic, stearic, oleic, and linoleic fatty acids, and other fatty acids present in lesser quantities.
- The essential oil preferably includes an antioxidant to inhibit spoilage of the oil.
- Conventional, food grade antioxidants are preferably used, including, but not limited to, tocopherol acetate (vitamin E acetate), propyl gallate, TBHQ (t-butyl hydroquinone), BHT (3,5-bis (t-butyl)-4-hydroxytoluene), and French maritime pine bark extract.
- The process for extracting Indian mulberry oil from its seeds typically involves obtaining Indian mulberry seeds that are dried to a moisture content less than 10%, by weight, and preferably from 5% to 8%, by weight. The seeds are cracked, ground, flaked, shredded, or mechanically reduced in size, typically from 2 to 20 mm. As used herein, ground seeds include seeds that may be ground, cracked, flaked, shredded, or otherwise reduced in size. The ground seeds are then pressed in a mechanical press or screw press to expel some of the oil. The remaining seed cake is mixed with a nonpolar extraction solvent. The extraction solvent is preferable food-grade. One currently preferred nonpolar solvent is hexane.
- Oil extraction with the nonpolar solvent preferably takes place at a temperature range between 30°C (80°F) and 90°C (200°F) and ranges from a time of 30 minutes up to 12 hours. It is presently preferred to complete the extraction step as quickly as possible. The nonpolar solvent is preferably removed from the extracted oil through flash evaporation.
- The oil from the mechanical press and from the nonpolar solvent extraction may be combined or further refined separately. The refining process removes impurities from the oil. Caustic, water, and phosphoric acid can be added to the oil to precipitate impurities.
- The precipitating agents and oil are mixed and heated to a temperature between 40°C (100°F)and 90°C (200°F), the currently preferred target temperature is between 75°C (170°F) and 80°C (180°F). The mixture is centrifuged to remove precipitated impurities that include, but are not limited to, insoluble gums, phosphatides, and free fatty acids.
- The oil can optionally be further refined by bleaching and deodorizing. Bleaching involves the addition of one or more filtering agents to the oil. The oil is filtered through a mechanical filter to remove the filtering agents. Currently preferred filtering agents include diatomaceous earth (D.E.) and activated charcoal. Bleaching removes color bodies and soap materials generated during the refining process. Bleaching is preferably done at temperatures between 40°C (100°F)and 90°C (200°F).
- The oil may or may not be vacuumed dried to remove any residual water. The oil is deodorized to remove volatile impurities. This involves steam distillation under a vacuum and at temperatures between 150°C (300°F) and 260°C (500°F). An antioxidant can be included with the extracted oil, as mentioned above.
- The present invention is directed to an essential oil product obtained from the Indian mulberry (Morinda citrifolia) plant and to the process of extracting and purifying the oil. The oil is extracted from Indian mulberry seeds. The seeds from the Indian mulberry fruit are dried and then packed in large containers for storage and transport. The seeds can be processed immediately or they can be stored for a period of time, usually up to about one year.
- The seeds are dried because residual water can contaminate the extraction solvent, which is oil based. Also the presence of water in the extraction process can cause oxidation of the oil. The rate of drying is preferably quick enough to be economical and slow enough to protect the oil from heat degradation. Drying usually takes from 10 to 100 days. The seeds are preferably dried in the sun or by a mechanical drier. The seeds are dried to a moisture content less than 10%, by weight, and preferably from about 5% to 8%, by weight. Conventional moisture detectors can be used to measure the moisture content of the seeds during and after the drying process.
- The seeds are cracked, ground, flaked, shredded, or mechanically reduced in size in order to facilitate the removal of natural occurring oil. As mentioned above, the term ground seeds include seeds that are ground, cracked, flaked, shredded, or otherwise reduced in size. The seeds are preferably ground through a grinder or flaker with a grinder plate size between about 2 mm to 20 mm hole size. The seeds are optimally reduced to a size falling in this range. The ground seed size is important because it effects the yield and quality of the extracted oil. Too large a flake size decreases the yield. Too small a flake size leaves a lot of undesired seed components in the oil.
- The ground seeds are preferably pressed in a mechanical press or screw press to expel some of the oil. The remaining seed cake is mixed with a nonpolar, food grade extraction solvent. Hexane is a currently preferred nonpolar solvent. The mixture of nonpolar solvent and seed cake is preferably heated to a temperature between 30°C (80°F) and 90°C (200°F) and for a time from about 30 minutes up to 12 hours. The nonpolar solvent mixes with the Indian mulberry oil remaining in the seeds and carries the oil out of the water based seed material matrix.
- Indian mulberry oil pressed from the seeds and from the hexane extraction may be combined or further refined separately to remove impurities from the oil. Such unwanted impurities include, but are not limited to, insoluble gums, phosphatides, and free fatty acids. Caustic, water, and phosphoric acid are currently preferred precipitating agents that can be added to the oil to precipitate impurities. The oil and precipitating agent mixture is preferably heated to a temperature between 40°C (100°F)and 90°C (200°F), and more preferably heated to a temperature between 75°C (170°F) to 80°C (180°F). The mixture is preferably centrifuged to remove the precipitated impurities.
- The oil may be optionally further refined by bleaching and deodorizing. Bleaching involves the addition of one or more filtering agents to the oil to remove color bodies and soap materials generated during the refining process. Currently preferred filtering agents include, but are not limited to diatomaceous earth (D.E.) and activated charcoal. The oil is filtered through a mechanical filter to remove the filtering agents. Bleaching is done at temperatures between 40°C (100°F) and 90°C (200°F). Residual water can be removed from the oil by vacuum drying.
- The oil is preferably deodorized to remove volatile impurities. This involves steam distillation under a vacuum. Typical distillation temperatures range from 150°C (300°F) and 260°C (500°F).
- An antioxidant can optionally be added to stabilize the oil for further processing or packaging. Suitable antioxidants include, but are not limited to, tocopherol acetate (vitamin E acetate), propyl gallate, TBHQ (t-butyl hydroquinone), BHT (3,5-bis (t-butyl)-4hydroxytoluene), French maritime pine bark extract. The Morinda citrifolia seed oil may be used in, but is not limited to massage oil, cosmetics, candles, and as a product by itself.
- The fragrance of the oil ranges from a nutty, mellow fragrance to a slightly sharp chemical solvent fragrance. The extracted oil appearance is from a rich golden yellow to a brownish tan color with a clear transparency, preferably free of foreign material or particulates.
- From an analysis of the Morinda citrifolia oil, the oil is mainly composed of fatty acids as triglycerides. The free fatty acid content typically ranges from 5 to 9 grams/100 grams oil. The peroxide value typically ranges from 3 to 6 MEQ/KG, and the vitamin E content typically ranges from 11 to 25 IU/100 gram. The approximate fatty acid composition of the oil is reported below in Table 1.
Table 1 Fatty Acid Wt. % Caprylic 0.5 Palmitic 8.4 Stearic 4.0 Oleic 13.8 Linoleic 66.8 Linolenic 0.2 Arachidic 0.5 Eicosenoic 0.2 Other fatty acids 5.6 - The foregoing concentrations in the extracted oil can vary from one batch to another, but the variations generally do not exceed 10%, by weight.
Claims (35)
- A process for extracting oil from Morinda citrifolia seeds comprising the steps of:drying the seeds to a moisture content less than 10%;cracking, flaking, or grinding the seeds to form ground seeds; andpressing the processed seeds to expel Morinda citrifolia oil.
- A process as claimed in Claim 1, further comprising the steps of:mixing the pressed, processed seeds with a nonpolar extraction solvent to allow Morinda citrifolia oil from the seeds to mix with the extraction solvent; andheating the mixture of seeds and extraction solvent to a temperature between 30°C (80°F) and 90°C (200°F) to extract Morinda citrifolia oil from the seeds.
- A process as claimed in Claim 2, wherein the mixture is heated for a period between 30 minutes and 12 hours.
- A process as claimed in Claim 2 or Claim 3, further comprising the step of removing the extraction solvent from the extracted Morinda citrifolia oil by evaporation.
- A process as claimed in any one of Claims 2 to 4, wherein the extraction solvent is a food-grade extraction solvent.
- A process as claimed in any one of Claims 2 to 5, wherein the extraction solvent is hexane.
- A process as claimed in any preceding claim, further comprising the step of removing impurities from the Morinda citrifolia oil.
- A process as claimed in Claim 7, wherein the impurities are precipitated by addition of a precipitating agent and removed from the Morinda citrifolia oil by centrifuge.
- A process as claimed in any preceding claim, further comprising the step of bleaching the Morinda citrifolia oil.
- A process as claimed in Claim 9, wherein the step of bleaching the Morinda citrifolia oil comprises:adding a filtering agent selected from diatomaceous earth (D.E.) andactivated charcoal to the Morinda citrifolia oil;heating the mixture of filtering agent and Morinda citrifolia oil to a temperature between 40°C (100°F) and 90°C (200°F); andremoving the filter agent by mechanical filtration.
- A process as claimed in any preceding claim, further comprising the step of deodorizing the Morinda citrifolia oil.
- A process as claimed in any preceding claim, wherein the seeds are processed to a size between 2 mm to 20 mm.
- A process as claimed in any preceding claim, further comprising the step of adding an antioxidant to the Morinda citrifolia oil.
- A process as claimed in Claim 13, wherein the antioxidant is selected form tocopherol acetate (vitamin E acetate), propyl gallate, TBHQ (t-butyl hydroquinone), BHT (3,5-bis(t-butyl)-4-hydroxytoluene), and French maritime pine bark extract.
- A process as claimed in any preceding claim, further comprising the step of removing volatile impurities by distilling the Morinda citrifolia oil.
- A process as claimed in any preceding claim, further comprising the step of removing residual water by vacuum drying the Morinda citrifolia oil.
- An essential oil comprising oil extracted from Morinda citrifolia seeds by the process of any preceding claim, wherein the extracted oil includes at least one of caprylic fatty acid; oleic fatty acid; and linoleic fatty acid;
- An essential oil as claimed in Claim 17, further comprising an antioxidant.
- An essential oil as claimed in Claim 18, wherein the antioxidant is selected from tocopherol acetate (vitamin E acetate), propyl gallate, TBHQ (t-butyl hydroquinone), BHT (3,5-bis(t-butyl)-4-hydroxytoluene), and French maritime pine bark extract.
- An essential oil as claimed in any one of Claims 17 to 19, comprising palmitic, stearic, oleic, and linoleic fatty acids.
- An essential oil as claimed in any one of Claims 17 to 20, wherein the oil extracted from Morinda citrifolia seeds further comprises at least one of:palmitic fatty acid;,stearic fatty acid;linolenic fatty acid;arachidic fatty acid; andeicosenoic fatty acid.
- An essential oil as claimed in any one of Claims 17 to 21, wherein the oil extracted from Morinda citrifolia seeds has a free fatty acid content ranging from 5 to 9 grams/100 grams oil.
- An essential oil as claimed in any one of Claims 17 to 22, wherein the oil extracted from Morinda citrifolia seeds has a peroxide value ranging from 3 to 6 MEQ/KG.
- An essential oil as claimed in any one of Claims 17 to 23, wherein the oil extracted from Morinda citrifolia seeds has a vitamin E content ranging from 11 to 25 IU/100 gram.
- An essential oil as claimed in any one of Claims 16 to 24, wherein the oil extracted from Morinda citrifolia seeds comprises a mixture of caprylic, palmitic, stearic, oleic, linoleic, linolenic, arachidic, and eicosenoic fatty acid.
- An essential oil as claimed in any one of Claims 16 to 25, wherein the oil extracted from Morinda citrifolia seeds comprises:0.5 wt. % caprylic fatty acid;8.4 wt. % palmitic fatty acid;4.0 wt. % stearic fatty acid;13.8.wt. % oleic fatty acid;66.8 wt. % linoleic fatty acid;0.2 wt. % linolenic fatty acid;0.5 wt. % arachidic fatty acid; and0.2 wt. % eicosenoic fatty acid;
wherein the foregoing concentrations can vary up to ±10%, by weight. - An essential oil as claimed in any one of Claims 16 to 26, wherein the extracted oil has a free fatty acid content ranging from 5 to 9 grams/100 grams oil; and an antioxidant.
- An essential oil as claimed in Claim 27, wherein the antioxidant is selected from tocopherol acetate (vitamin E acetate), propyl gallate, TBHQ (t-butyl hydroquinone), BHT (3,5-bis(t-butyl)-4-hydroxytoluene), and French maritime pine bark extract.
- An essential oil as claimed in any one of Claims 17 to 28, wherein the oil extracted from Morinda citrifolia seeds is bleached.
- An essential oil as claimed in any one of Claims 17 to 29, wherein the oil extracted from Morinda citrifolia seeds is deodorized.
- An essential oil as claimed in any one of Claims 17 to 30, wherein the oil extracted from Morinda citrifolia seeds has a peroxide value ranging from 3 to 6 MEQ/KG.
- An essential oil as claimed in any one of Claims 17 to 31, wherein the oil extracted from Morinda citrifolia seeds has a vitamin E content ranging from 11 to 25 IU/100 gram.
- A massage oil containing an essential oil as claimed in any one or more of Claims 17 to 32.
- A cosmetic product containing an essential oil as claimed in any one or more of Claims 17 to 32.
- A candle containing an essential oil as claimed in any one or more of Claims 17 to 32.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US384785 | 1999-08-27 | ||
US09/384,785 US6214351B1 (en) | 1999-08-27 | 1999-08-27 | Morinda citrifolia oil |
PCT/US2000/023394 WO2001015537A1 (en) | 1999-08-27 | 2000-08-25 | Morinda citrifolia oil |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1223811A1 EP1223811A1 (en) | 2002-07-24 |
EP1223811A4 EP1223811A4 (en) | 2004-09-15 |
EP1223811B1 true EP1223811B1 (en) | 2009-01-14 |
Family
ID=23518756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00961370A Expired - Lifetime EP1223811B1 (en) | 1999-08-27 | 2000-08-25 | Morinda citrifolia oil |
Country Status (8)
Country | Link |
---|---|
US (2) | US6214351B1 (en) |
EP (1) | EP1223811B1 (en) |
JP (1) | JP4198913B2 (en) |
AT (1) | ATE420559T1 (en) |
AU (1) | AU7333100A (en) |
DE (1) | DE60041412D1 (en) |
MX (1) | MXPA02002145A (en) |
WO (1) | WO2001015537A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737089B2 (en) * | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
US20020068102A1 (en) * | 2000-12-01 | 2002-06-06 | Su Chen Xing | Reducing cellular damage in the human body |
US7048952B2 (en) * | 2002-05-21 | 2006-05-23 | Morinda, Inc. | Formulation for inhibiting fungal and microbial growth comprising morinda citrifolia puree juice |
US20110171333A1 (en) * | 2000-12-05 | 2011-07-14 | Bryant Wadsworth | Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products |
US20110217394A1 (en) * | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
US7244463B2 (en) * | 2005-10-18 | 2007-07-17 | Tahitian Noni International, Inc. | Garcinia mangostana L. enhanced animal food product |
US8790727B2 (en) * | 2000-12-05 | 2014-07-29 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
US8574642B2 (en) | 2000-12-05 | 2013-11-05 | Tahitian Noni International, Inc. | Antiviral Morinda citrifolia L. based formulations and methods of administration |
US6855345B2 (en) * | 2001-11-02 | 2005-02-15 | Morinda, Inc. | Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions |
US20040192761A1 (en) * | 2003-03-25 | 2004-09-30 | Palu Afa Kehaati | Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor |
US20120237626A9 (en) * | 2000-12-05 | 2012-09-20 | Palu Afa Kehaati | Profiles of lipid proteins and inhibiting HMG-CoA reductase |
US8652546B2 (en) | 2007-09-06 | 2014-02-18 | Tahitian Noni International, Inc. | Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals |
US20070196527A1 (en) * | 2006-02-23 | 2007-08-23 | Jensen Claude J | Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions |
US6589514B2 (en) * | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
WO2002083159A1 (en) * | 2001-04-17 | 2002-10-24 | Morinda, Inc. | Palliative effects of morinda citrifolia oil and juice |
US8012517B2 (en) * | 2001-08-31 | 2011-09-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice Morinda citrifolia |
US7070813B2 (en) * | 2001-11-02 | 2006-07-04 | Morinda, Inc. | Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor |
US7442395B2 (en) * | 2002-11-14 | 2008-10-28 | Tahitian Noni International, Inc. | Formulation for treating candidiasis using Morinda citrifolia |
US20110160057A1 (en) * | 2001-11-14 | 2011-06-30 | Bryant Wadsworth | Morinda Citrifolia Based Antimicrobial Formulations |
US7189419B2 (en) * | 2002-12-17 | 2007-03-13 | Avon Products, Inc. | Use of active extracts to lighten skin, lips, hair, and/or nails |
US20060269630A1 (en) * | 2003-04-16 | 2006-11-30 | Palu Afa K | Morinda citrifolia as a 5-Lipoxygenase inhibitor |
US20050106275A1 (en) * | 2003-05-02 | 2005-05-19 | Chen Su | Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells |
JP4073826B2 (en) * | 2003-06-04 | 2008-04-09 | タヒチアン ノニ インターナショナル インコーポレーテッド | Agricultural vital agent containing extract of Yaeyama Aoki |
US20070259060A1 (en) * | 2003-08-12 | 2007-11-08 | Mian-Ying Wang | Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane |
US20050260291A1 (en) * | 2004-03-10 | 2005-11-24 | Palu Afa K | Methods and compositions for reactivating acetylcholinesterase |
US7897194B2 (en) * | 2006-04-18 | 2011-03-01 | Botanic Oil Innovations, Inc. | Synergistic super potent antioxidant cold pressed botanic oil blends |
US7955834B2 (en) * | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
WO2006028826A2 (en) * | 2004-09-01 | 2006-03-16 | Paulus Wang | Morinda citrifolia-based formulations and methods for weight management |
US20060141076A1 (en) * | 2004-11-01 | 2006-06-29 | Palu Afa K | Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase |
US20060204601A1 (en) * | 2005-03-09 | 2006-09-14 | Palu Afa K | Formulations and methods for preventing and treating substance abuse and addiction |
US20060280818A1 (en) * | 2005-05-26 | 2006-12-14 | Palu Afa K | Nicotinic acetylcholine receptor antagonist |
US20070122507A1 (en) * | 2005-05-26 | 2007-05-31 | Palu Afa K | Histone deacetylase and tumor necrosis factor converting enzyme inhibition |
US20070166417A1 (en) * | 2005-11-29 | 2007-07-19 | Palu Afa K | Formulation and Methods for Use of Morinda Citrifolia Seed Oil |
US20070154579A1 (en) * | 2005-11-29 | 2007-07-05 | Palu Afa K | Morinda Citrifolia Based Formulation And Methods For Weight Management |
US20070237848A1 (en) * | 2005-12-21 | 2007-10-11 | Brad Rawson | MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS |
US20070281903A1 (en) * | 2006-05-04 | 2007-12-06 | Palu Afa K | Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX |
US8535741B2 (en) | 2006-05-12 | 2013-09-17 | Morinda, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
US8025910B2 (en) | 2006-05-12 | 2011-09-27 | Tahitian Noni International, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
EP1873230A1 (en) * | 2006-06-29 | 2008-01-02 | Spaas Kaarsen | Candle and candle production process. |
US20080226758A1 (en) * | 2006-11-28 | 2008-09-18 | Shixin Deng | Lipoxygenase and Cyclooxygenase Inhibition |
US20080213415A1 (en) * | 2007-02-08 | 2008-09-04 | Palu Afa K | Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations |
US8591959B1 (en) * | 2007-03-27 | 2013-11-26 | Angel Dayna Kelly | Body spritzer formulation and application process |
US8668944B2 (en) * | 2007-04-03 | 2014-03-11 | Donna Greco | Topical oil for treating physical ailments and method for making and applying the same |
US20080317890A1 (en) * | 2007-06-21 | 2008-12-25 | Claude Jarakae Jensen | Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical |
US20090196944A1 (en) * | 2008-02-01 | 2009-08-06 | Brad Rawson | Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS |
JP5352194B2 (en) | 2008-11-11 | 2013-11-27 | 高砂香料工業株式会社 | Method for producing refined essential oil |
US20110206786A1 (en) * | 2010-02-23 | 2011-08-25 | Brett Justin West | Acai and Iridoid Based Formulations |
US9402415B2 (en) | 2010-04-21 | 2016-08-02 | R. J. Reynolds Tobacco Company | Tobacco seed-derived components and materials |
US9458476B2 (en) | 2011-04-18 | 2016-10-04 | R.J. Reynolds Tobacco Company | Method for producing glycerin from tobacco |
US20130125907A1 (en) | 2011-11-17 | 2013-05-23 | Michael Francis Dube | Method for Producing Triethyl Citrate from Tobacco |
US9289011B2 (en) | 2013-03-07 | 2016-03-22 | R.J. Reynolds Tobacco Company | Method for producing lutein from tobacco |
US20140356295A1 (en) | 2013-06-03 | 2014-12-04 | R.J. Reynolds Tobacco Company | Cosmetic compositions comprising tobacco seed-derived component |
US9265284B2 (en) | 2014-01-17 | 2016-02-23 | R.J. Reynolds Tobacco Company | Process for producing flavorants and related materials |
US10881133B2 (en) | 2015-04-16 | 2021-01-05 | R.J. Reynolds Tobacco Company | Tobacco-derived cellulosic sugar |
US10499684B2 (en) | 2016-01-28 | 2019-12-10 | R.J. Reynolds Tobacco Company | Tobacco-derived flavorants |
CN106176324B (en) * | 2016-08-31 | 2019-01-29 | 深圳市容大生物技术有限公司 | A kind of Whitening sunscreen cream and preparation method thereof containing Noni fruit essential oil |
US11091446B2 (en) | 2017-03-24 | 2021-08-17 | R.J. Reynolds Tobacco Company | Methods of selectively forming substituted pyrazines |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4543212A (en) | 1978-01-19 | 1985-09-24 | Research Corporation Of The University Of Hawaii | Xeronine, a new alkaloid, useful in medical, food and industrial fields |
US4666606A (en) | 1978-01-19 | 1987-05-19 | The Research Corporation Of The University Of Hawaii | Method for eliminating grease and odors from sewage systems |
US4409144A (en) | 1978-01-19 | 1983-10-11 | Research Corporation Of The University Of Hawaii | Xeronine, a new alkaloid, useful in medical, food and industrial fields |
FR2617848B1 (en) | 1987-07-10 | 1990-01-05 | Guyomarch Sa Ets | POLYSACCHARIDES EXTRACTED, IN PARTICULAR, FROM PLANTS USEFUL AS MEDICAMENTS AND FOOD ADDITIVES |
US5268467A (en) | 1988-05-23 | 1993-12-07 | Verbiscar Anthony J | Immunomodulatory polysaccharide fractions from Astragalus plants |
EP0432210B1 (en) | 1988-09-05 | 1993-11-18 | Institut National De La Recherche Agronomique (Inra) | Process for treating products rich in plant cell walls, in particular rich in pectins, said pectins, the extraction residues from the process, their use and compositions containing them |
FR2673639B1 (en) * | 1991-03-08 | 1996-06-07 | Nigiko Sa | FRACTIONS ENRICHED IN FATTY ACID EXTRACTED FROM MORINDA AND INSECTICIDE COMPOSITIONS CONTAINING SAID FRACTIONS AND / OR FATTY ACIDS. |
US5288491A (en) | 1992-09-24 | 1994-02-22 | Herbert Moniz | Noni (Morinda Citrifolia) as a pharmaceutical product |
US5736174A (en) * | 1994-03-14 | 1998-04-07 | Arco Chemical Technology, L.P. | Alkoxylated alcohol fat substitutes |
JPH08217686A (en) * | 1995-02-08 | 1996-08-27 | Terumo Corp | Anti-helicovbacter pylori medicine containing extract of dried root of morinda citrifolia |
US5843499A (en) * | 1995-12-08 | 1998-12-01 | The United States Of America As Represented By The Secretary Of Agriculture | Corn fiber oil its preparation and use |
US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
US6139897A (en) * | 1998-03-24 | 2000-10-31 | Kao Corporation | Oil or fat composition containing phytosterol |
-
1999
- 1999-08-27 US US09/384,785 patent/US6214351B1/en not_active Expired - Lifetime
-
2000
- 2000-03-14 US US09/523,865 patent/US6417157B1/en not_active Expired - Lifetime
- 2000-08-25 JP JP2001519766A patent/JP4198913B2/en not_active Expired - Lifetime
- 2000-08-25 AU AU73331/00A patent/AU7333100A/en not_active Abandoned
- 2000-08-25 EP EP00961370A patent/EP1223811B1/en not_active Expired - Lifetime
- 2000-08-25 WO PCT/US2000/023394 patent/WO2001015537A1/en active Application Filing
- 2000-08-25 MX MXPA02002145A patent/MXPA02002145A/en active IP Right Grant
- 2000-08-25 AT AT00961370T patent/ATE420559T1/en not_active IP Right Cessation
- 2000-08-25 DE DE60041412T patent/DE60041412D1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60041412D1 (en) | 2009-03-05 |
MXPA02002145A (en) | 2003-08-20 |
US6214351B1 (en) | 2001-04-10 |
JP2003508554A (en) | 2003-03-04 |
EP1223811A1 (en) | 2002-07-24 |
AU7333100A (en) | 2001-03-26 |
ATE420559T1 (en) | 2009-01-15 |
JP4198913B2 (en) | 2008-12-17 |
US6417157B1 (en) | 2002-07-09 |
WO2001015537A1 (en) | 2001-03-08 |
EP1223811A4 (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1223811B1 (en) | Morinda citrifolia oil | |
CA1126498A (en) | Process for the preparation of antioxygen substances | |
US20200397012A1 (en) | Compounds extracted from plant matter and methods of preparation thereof | |
Guillaume et al. | Argan [Argania spinosa (L.) skeels] oil | |
JP2007056181A (en) | Functional olive oil, method for producing the same and use thereof | |
CA3065480C (en) | Process for producing oils and defatted meals by solid/liquid extraction | |
US8574642B2 (en) | Antiviral Morinda citrifolia L. based formulations and methods of administration | |
JP2009536957A (en) | Methods and compositions for administering bioactive compounds derived from Morinda citrifolia | |
Khan et al. | Comparative evaluation of physiochemical and GC-MS analysis of sour oranges and sweet oranges peels oil | |
KR20130020440A (en) | A production method of grape juice having the extraction process of grape seeds | |
ERKAÇ et al. | Application of Gallic Acid Produced from Horse Chestnut (Aesculus hippocastanum) Shell in Table Olive Maturation | |
US20230190847A1 (en) | Process for preparing a total extract or a filtrate enabling the stabilization of fresh plant matter | |
KR0141650B1 (en) | Extracts crude drug whc | |
JP2010013383A (en) | Antioxidant composed of extract of eugenia michelli lamarck, psidium cattleianum or the like | |
KR101068890B1 (en) | A method for extracting and concentrating polyphenol from grape branch | |
Kays et al. | Chronological sequence of pigment development in the kernels of pecan cultivar ‘Stuart’ | |
CN117801875A (en) | Efficient oil extraction method of oil tea | |
OA20857A (en) | Process for the production of virgin palm kernel oil by solvent and by cold separation. | |
KR100682622B1 (en) | A preparation method of grape seed oil and tea with high quality using organically grown grapesVitis vinifera L. | |
Yimam | ADDIS ABABA INSTITUTE OF TECHNOLOGY (AAiT) | |
Stella et al. | Extraction, Physicochemical, Phytochemical Analysis And Identification Of Some Important Compounds Of Monodora Myristica (African Nutmeg) Seed Oil | |
Mustakim | Soxhlet extraction of ascorbic acid from guava | |
Sharuddin | Palm Kernel Testa Removal and Its Effects on Extracted Oil Quality | |
Khalifa et al. | Evaluation and utilization of olive extracts polyphenols as natural antioxidants | |
MIEDICA | very hard, cut with difficulty; upon transverse section white and |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020308 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20020308;LT PAYMENT 20020308;LV PAYMENT 20020308;MK PAYMENT 20020308;RO PAYMENT 20020308;SI PAYMENT 20020308 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040730 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TAHITIAN NONI INTERNATIONAL, INC |
|
17Q | First examination report despatched |
Effective date: 20080212 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE S.A. |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60041412 Country of ref document: DE Date of ref document: 20090305 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20090114 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20091015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090415 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20110824 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120826 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20140829 Year of fee payment: 15 Ref country code: DE Payment date: 20140825 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20140822 Year of fee payment: 15 Ref country code: FR Payment date: 20140828 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20140929 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60041412 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160301 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |